Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.

13 March 2021 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

7 More presentations in this session

Presentation thumbnail

Trends in major bleeding events in patients with acute coronary syndrome.

Doctor A. Cordero (Alicante, ES)

Presentation thumbnail

Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis

Ms A. Abdul Razzack (Hyderabad, IN)

Presentation thumbnail

Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis

Ms A. Abdul Razzack (Hyderabad, IN)

Presentation thumbnail

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

Doctor H. Wang (Beijing, CN)

Presentation thumbnail

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

Doctor H. Wang (Beijing, CN)

Access the full session

Session thumbnail

Live Abstract session - Antithrombotics and bleeding

The Event

ACVC 2021

13 March - 14 March 2021

You may be interested in

Congress Presentation

State-of-the-art lecture on pharmacotherapy for acute coronary syndromes

Congress Presentation

State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources